Expertise in
21
conditions

Dr. Daniel Wang

Hematology | Oncology
Office
6620 Main St Ste 1350, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
21
conditions
Office
6620 Main St Ste 1350, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Wang is a Hematologist and an Oncologist in Houston, Texas. Dr. Wang is highly rated in 21 conditions, according to our data. His top areas of expertise are Mesothelioma, Melanoma, Bone Tumor, and Liposarcoma.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
UT Of Texas Southwestern University Hospital - William P. Clements Jr.
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Office
6620 Main St Ste 1350, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors
A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors
Enrollment Status: Recruiting
Publish Date: February 06, 2026
Intervention Type: Biological
Study Drug: HER2 CAR T-Cells CAdVEC
Study Phase: Phase 1
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Completed
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies
A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Phase: Phase 1
View 2 Less Clinical Trial

13 Total Publications

Language barriers are associated with advanced presentation of melanoma in Hispanic patients: A retrospective case series.
Language barriers are associated with advanced presentation of melanoma in Hispanic patients: A retrospective case series.
Journal: Journal of the American Academy of Dermatology
Published: May 13, 2025
Similar Doctors
William Wierda
Expertise in
28
conditions
Dr. William Wierda
Hematology | Oncology
Expertise in
28
conditions
Dr. William Wierda
Hematology | Oncology

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
 (231.3 miles away)
713-792-7040
Languages Spoken:
English
See accepted insurances

William Wierda is a Hematologist and an Oncologist in Houston, Texas. Dr. Wierda is highly rated in 28 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
18
conditions
Dr. Philip Thompson
Hematology | Oncology
Expertise in
18
conditions
Dr. Philip Thompson
Hematology | Oncology

Office

1400 Pressler St, 
Houston, TX 
 (231.5 miles away)
713-792-7430
Languages Spoken:
English
See accepted insurances

Philip Thompson is a Hematologist and an Oncologist in Houston, Texas. Dr. Thompson is highly rated in 18 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Aspiration, and Splenectomy.

Expertise in
9
conditions
Dr. Carl Allen
Hematology | Oncology
Expertise in
9
conditions
Dr. Carl Allen
Hematology | Oncology

Office

1102 Bates Ave Ste 750, 
Houston, TX 
 (231.3 miles away)
832-824-4312
Languages Spoken:
English
See accepted insurances

Carl Allen is a Hematologist and an Oncologist in Houston, Texas. Dr. Allen is highly rated in 9 conditions, according to our data. His top areas of expertise are Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Hemophagocytic Lymphohistiocytosis, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wang's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile